Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus

OBJECTIVE: This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo on rash and arthritis measures with different stringency in patients with moderate to severe SLE (phase IIb; MUSE; NCT01438489). Subgroups were analysed by type I interferon gene signature (IFNGS test–high or te...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lupus Sci Med
Hlavní autoři: Merrill, Joan T, Furie, Richard, Werth, Victoria P, Khamashta, Munther, Drappa, Jorn, Wang, Liangwei, Illei, Gabor, Tummala, Raj
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2018
Témata:
Clinical Trials and Drug Discovery
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6280909/
https://ncbi.nlm.nih.gov/pubmed/30588322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000284
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky